BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Remicade is a prescription medication approved by the Food and Drug Administration (FDA) to treat ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Remicade is not FDA-approved for treating hidradenitis suppurativa (HS), but it is sometimes prescribed off-label to treat cases of HS that have not responded to other treatments. In cases of HS, Remicade is often prescribed in combination with Methotrexate. Remicade may be referred to by its drug name, Infliximab.
Remicade is an immunomodulator, or in other words, a drug that modulates the immune system. It is considered a biologic disease-modifying antirheumatic drug (DMARD). Remicade is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Remicade is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks.
How do I take it?
After initial loading doses, Remicade is administered every eight weeks by intravenous infusion in a clinical setting.
Remicade is available as a vial.
The FDA-approved label for Remicade lists common side effects including headache, cold symptoms, infusion reactions, and abdominal pain.
Rare but serious side effects listed for Remicade include heart and liver failure, blood disorders, potentially life-threatening infections and allergic reactions, stroke, lupus-like syndrome, demyelinating disease such as multiple sclerosis, and increased risk for developing certain types of cancer including lymphoma.
For more details about this treatment, visit:
Remicade – Janssen
Review of Current Immunologic Therapies for Hidradenitis Suppurativa – International Journal of Rheumatology